These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

10482 related items for PubMed ID: 11583285

  • 1. Therapeutic implications of the kinetics of immunomodulation during single or combined treatment of melanoma patients with dacarbazine and interferon-alpha.
    Konjević G, Jović V, Radulović S, Jelić S, Dzodić R, Spuzić I.
    Neoplasma; 2001; 48(3):175-81. PubMed ID: 11583285
    [Abstract] [Full Text] [Related]

  • 2. [Correlation between functional capability and phenotypic characteristics of peripheral blood lymphocytes in patients with malignant melanoma].
    Konjević G, Jović V, Radomirović V, Spuzić I.
    Glas Srp Akad Nauka Med; 2002; (47):121-36. PubMed ID: 16078447
    [Abstract] [Full Text] [Related]

  • 3. Changes in immunological parameters after combination adjuvant therapy with intravenous DTIC, ACNU, and VCR, and local injection of IFN-beta (DAV + IFN-beta therapy) into malignant melanoma.
    Umeda T, Aoki K, Yokoyama A, Ohara H, Hayashi O, Tanaka K, Nishioka K.
    J Dermatol; 1998 Sep; 25(9):569-72. PubMed ID: 9798342
    [Abstract] [Full Text] [Related]

  • 4. [Chemoimmunotherapy with dacarbazine and aranose combined with interferon-alpha in disseminated cutaneous melanoma].
    Gershanovich ML, Akimov MA.
    Vopr Onkol; 2004 Sep; 50(2):179-83. PubMed ID: 15176220
    [Abstract] [Full Text] [Related]

  • 5. The expression of cytotoxic mediators is altered in mononuclear cells of patients with melanoma and increased by interferon-alpha treatment.
    Guillot B, Portalès P, Thanh AD, Merlet S, Dereure O, Clot J, Corbeau P.
    Br J Dermatol; 2005 Apr; 152(4):690-6. PubMed ID: 15840100
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. [Interferon-alpha can improve the prognosis in high-risk melanoma. Combination of surgery, cytostatics and natural IFN-alpha doubled the survival rate].
    Strannegärd O, Thorén FB, Lundgren E.
    Lakartidningen; 2005 Apr; 105(6):358-61. PubMed ID: 18380352
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Complex combination biochemotherapy regimen in advanced metastatic melanoma in a non-intensive care unit: toxicity or benefit?
    Hofmann MA, Sterry W, Trefzer U.
    Jpn J Clin Oncol; 2007 Mar; 37(3):224-9. PubMed ID: 17472972
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. IL-2-mediated augmentation of NK-cell activity and activation antigen expression on NK- and T-cell subsets in patients with metastatic melanoma treated with interferon-alpha and DTIC.
    Konjević G, Jović V, Jurisić V, Radulović S, Jelić S, Spuzić I.
    Clin Exp Metastasis; 2003 Mar; 20(7):647-55. PubMed ID: 14669796
    [Abstract] [Full Text] [Related]

  • 17. [Combination of fotemustine-dacarbazine and interferon alpha in the treatment of metastatic malignant melanoma].
    Célérier P, Dreno B, Bureau B, Litoux P.
    Ann Dermatol Venereol; 1993 Mar; 120(6-7):437-40. PubMed ID: 8279787
    [Abstract] [Full Text] [Related]

  • 18. Chemoimmunotherapy with dacarbazine, cisplatin, interferon-alpha2b and interleukin-2 versus two cycles of dacarbazine followed by chemoimmunotherapy in patients with metastatic melanoma: a randomised phase II study of the European Organization for Research and Treatment of Cancer Melanoma Group.
    Punt CJ, Suciu S, Gore MA, Koller J, Kruit WH, Thomas J, Patel P, Lienard D, Eggermont AM, Keilholz U.
    Eur J Cancer; 2006 Nov; 42(17):2991-5. PubMed ID: 17023156
    [Abstract] [Full Text] [Related]

  • 19. CD69 on CD56+ NK cells and response to chemoimmunotherapy in metastatic melanoma.
    Konjević G, Jović V, Vuletić A, Radulović S, Jelić S, Spuzić I.
    Eur J Clin Invest; 2007 Nov; 37(11):887-96. PubMed ID: 17973783
    [Abstract] [Full Text] [Related]

  • 20. Local immunotherapy with interferon-alpha in metastatic pleural and peritoneal effusions: correlation with immunologic parameters.
    Stathopoulos GP, Baxevanis CN, Papadopoulos NG, Zarkadis IK, Papacostas P, Michailakis E, Tsiatas ML, Papamichail M.
    Anticancer Res; 1996 Nov; 16(6B):3855-60. PubMed ID: 9042270
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 525.